Background-Prior trials suggest it is safe to defer transfusion at hemoglobin levels above 7-8 g/dL in most patients. Patients with acute coronary syndrome may benefit from higher hemoglobin levels.

This paper describes the extension of a well proven state-of-the-art simulation tool for coupled floating structures to accommodate offshore wind turbine applications, both floating and fixed. All structural parts, i.e. rotor blades, hub, nacelle, tower, vessel and mooring system, are included in the finite element model of the complete system. The aerodynamic formulation is based on the blade element momentum theory. A control algorithm is used for regulation of blade pitch angle and electrical torque. The system response is calculated by nonlinear time domain analysis. This approach ensures dynamic equilibrium every time step and gives a proper time domain interaction between the blade dynamics, the mooring dynamics and the tower motions. The developed computer code provides a tool for efficient analysis of motions, support forces and power generation potential, as influenced by waves, wind, and current. Some key results from simulations with wind and wave loading are presented in the paper. The results are compared with results obtained with a rigid blade model and quasi-static model of the anchor lines. The modelled wind turbine is the NREL offshore 5-MW baseline wind turbine, specifications of which are publicly available. In the accompanying paper, Global Analysis of a Floating Wind Turbine Using an Aero-Hydro-Elastic Numerical Model. Part 2: Benchmark Study, results from the new analysis tool are benchmarked against results from other analysis tools.

This paper presents numerical studies of the dynamic responses of a jacket-type offshore wind turbine using both decoupled and coupled models. In the decoupled (hydroelastic) model, the wind load is included through time-dependent forces and moments at a single node on the top of the tower. The coupled model is a hydro-servo-aero-elastic representation of the system. The investigated structure is the OC4 (Offshore Code Comparison Collaboration Continuation) jacket foundation supporting the NREL 5-MW wind turbine in a water depth of 50m. Different operational wind and wave loadings at an offshore site with relatively high soil stiffness are investigated. The objective of this study is to evaluate the applicability of the computationally efficient linear decoupled model by comparing with the results obtained from the nonlinear coupled model. Good agreement was obtained in the eigen-frequency analysis, decay tests, and wave-only simulations. In order to obtain good results in the combined wind and wave simulations, two different strategies were applied in the decoupled model, which are 1) Wind loads obtained from the coupled model were applied directly as timedependent point loads in the decoupled model; and 2) The thrust and torque from an isolated rotor model were used as wind loads on the decoupled model together with a linear aerodynamic damper. It was found that, by applying the thrust force from an isolated rotor model in combination with linear damping, reasonable agreement could be obtained between the decoupled and coupled models in combined wind and wave simulations.

Background Cardiac amyloidosis, typically from abnormal deposition of AL or ATTR amyloid protein, can result in heart failure requiring transplantation (HTx). The role of mechanical circulatory support (MCS) is not well‐established. The purpose of this study was to present our experience with MCS in patients with cardiac amyloidosis. Methods Consecutive patients with cardiac amyloidosis who received MCS at Cedars‐Sinai Medical Center between 2010 and 2018 were reviewed. Clinical characteristics and outcomes were compared to a control group of MCS patients without amyloid matched 2:1 for age and INTERMACS Profile. Results 11 amyloid patients underwent durable MCS, two with paracorporeal biventricular assist devices and 9 with total artificial hearts. No patients received isolated left ventricular assist device support. By 1 year, 9 (82%) of patients in the MCS‐Amyloid group had been transplanted and 2 (18%) had died. In the MCS‐No Amyloid group, by 1 year, 8 (36%) of patients had been transplanted, 10 (46%) had died, and 4 (18%) were still living with MCS. Conclusions Over a 9‐year period, patients with amyloid cardiomyopathy who required MCS at our institution all received durable biventricular MCS. For carefully selected patients, this approach is feasible with acceptable outcomes as bridge to transplantation.